IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics


IGM BIOSCIENCES, INC. (IGMS): $16.56

0.24 (+1.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IGMS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IGMS Stock Price Chart Interactive Chart >

Price chart for IGMS

IGMS Price/Volume Stats

Current price $16.56 52-week high $99.44
Prev. close $16.32 52-week low $12.74
Day low $15.90 Volume 233,600
Day high $17.03 Avg. volume 875,647
50-day MA $18.56 Dividend yield N/A
200-day MA $37.64 Market Cap 704.25M

IGM BIOSCIENCES, INC. (IGMS) Company Bio


IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.


IGMS Latest News Stream


Event/Time News Detail
Loading, please wait...

IGMS Latest Social Stream


Loading social stream, please wait...

View Full IGMS Social Stream

Latest IGMS News From Around the Web

Below are the latest news stories about IGM Biosciences Inc that investors may wish to consider to help them evaluate IGMS as an investment opportunity.

IGM Biosciences: Interesting Science, Poor Trial Data

No summary available.

Seeking Alpha | February 23, 2022

Why Did IGM Biosciences Shares Advance Today?

IGM Biosciences Inc (NASDAQ: IGMS ) has progressed two Phase 1 trials evaluating IGM-6268 , an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19. The first Phase 1 trial is a single (SAD) and multiple (MAD) ascending dose study to assess Full story available on Benzinga.com

Benzinga | February 9, 2022

IGM Biosciences updates on early-stage studies for intranasal COVID-19 therapy

IGM Biosciences (IGMS) announced upcoming milestones for the company’s early-stage trials for IGM-6268, an investigational monoclonal antibody, being developed as a treatment or…

Seeking Alpha | February 9, 2022

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested –

GlobeNewswire | February 9, 2022

IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference

MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022 at 1:00 p.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’

Yahoo | February 3, 2022

Read More 'IGMS' Stories Here

IGMS Price Returns

1-mo -7.07%
3-mo 2.22%
6-mo -65.77%
1-year -77.82%
3-year N/A
5-year N/A
YTD -43.54%
2021 -66.78%
2020 131.37%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7278 seconds.